| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 16th December 2020 | William Grossman | 2,117 | Open or private sale | $31.35 | $66,367.95 |
| 2nd October 2020 | William Grossman | 100,000 | Grant/award etc. | $0.00 | |
| 31st July 2020 | William Grossman | 100 | Open or private purchase | $19.77 | $1,977.00 |
| 31st July 2020 | William Grossman | 100 | Open or private purchase | $19.68 | $1,967.56 |
| 4th June 2020 | William Grossman | 55,000 | Grant/award etc. | $0.00 | |
| 29th May 2020 | Shane Ward | 107 | Payment by withholding | $7.63 | $816.41 |
| 17th March 2020 | Richard A. Fair | 5,000 | Open or private purchase | $4.00 | $19,998.50 |
| 3rd January 2020 | Rosemary Y. Williams | 781 | Exercise of derivative | $0.00 | |
| 3rd January 2020 | Alan K. Smith | 1,563 | Exercise of derivative | $0.00 | |
| 3rd January 2020 | Rosemary Y. Williams | 295 | Payment by withholding | $1.40 | $413.00 |
Bellicum Pharmaceuticals
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Bellicum Pharmaceuticals, Inc. focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. It uses its proprietary chemical induction of dimerization that controls components of the immune system in real time.
Ticker: BLCM
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1358403
Employees: 107
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $66 M (0%)
Assets, Current: $68 M (-39%)
Property, Plant and Equipment, Net: $2 M (-36%)
Other Assets, Noncurrent: $341 Th (-58%)
Assets: $72 M (-37%)
Long-term Debt, Current Maturities: $6 M (-41%)
Accounts Payable, Current: $2 M (-5%)
Accrued Liabilities, Current: $7 M (-27%)
Liabilities, Current: $79 M (-16%)
Long-term Debt, Excluding Current Maturities: $21 M (-19%)
Liabilities: $100 M (-17%)
Common Stock, Value, Issued: $51 Th (-89%)
Common Stock, Shares, Issued: $5 M (1%)
Additional Paid in Capital, Common Stock: $515 M (0%)
Retained Earnings (Accumulated Deficit): $559 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $389 Th (18%)
Treasury Stock, Value: $51 Th (0%)
Treasury Stock, Shares: $677 Th (0%)
Stockholders' Equity (Parent): $49 M (0%)
Liabilities and Equity: $72 M (-37%)
Research and Development: $12 M (-47%)
General and Administrative Expenses: $4 M (-52%)
Operating Income/Loss: $12 M (-55%)
Other Income, net: $31 M (4041%)
News
Bellicum Enrolls First Patient in Phase 1/2 Clinical Trial for BPX-603
10th December 2020
DXP Enterprises Reports Third Quarter 2020 Results
6th November 2020
17 Arrested For Running Fake Call Centre In Delhi: Police
6th November 2020
Ubiquiti Inc. Reports First Quarter Fiscal 2021 Financial Results
6th November 2020